Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Construction in Progress: 2016

  • Voyager Therapeutics' Construction in Progress was N/A to $3.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2016, which is N/A change from last year.
  • Latest data reveals that Voyager Therapeutics reported Construction in Progress of $3.0 million as of Q4 2016.
  • Voyager Therapeutics' 5-year Construction in Progress high stood at $3.0 million for Q4 2016, and its period low was $3.0 million during Q4 2016.
  • Its 1-year average for Construction in Progress is $3.0 million, with a median of $3.0 million in 2016.